Skip to main content
TipRanks
Go Ultimate75% OFF

PDS Biotechnology (PDSB) Stock Price & Analysis

919 Followers

PDSB Stock Chart & Stats

$0.78-$0.11(-12.21%)
At close: 4:00 PM EST
$0.5$1$1.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.76 - $0.92
52-Week Range
$0.20 - $1.79
Previous Close
$0.89
Volume
N/A
Average Volume (3M)
7.00M
Market Cap
$82.33M
Enterprise Value
$38.79M
Total Cash (Recent Filing)
$15.25B
Total Debt (Recent Filing)
$33.52M
Price to Earnings (P/E)
―
Beta
2.76
Next Earnings
Apr 01, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Promising PDS0301 Clinical Data

Encouraging Phase 2 outcomes in difficult-to-treat metastatic colorectal cancer support PDS0301’s potential clinical differentiation. The data provide a basis for designing a registrational Phase 3 program and may improve partnering prospects if durability and benefit are confirmed.

Validated PDS0101 Oncology Results

The PDS0101 data indicate meaningful activity in HPV16-positive head and neck cancer, a focused indication with substantial unmet need. External interest and a negotiation window with NantWorks could help fund later development and preserve strategic optionality.

Strategic Financing And Debt Retirement

Debt retirement simplifies obligations while new financing supports working capital and continued clinical development. Nant-linked funding commitments and a potential PDS0101 licensing relationship may provide strategic support as the company advances its lead program toward later-stage testing.

Bears Say

Persistent Pre-revenue Losses

PDS Biotechnology has not yet demonstrated commercial revenue or operating leverage, leaving financial performance dependent on future clinical and regulatory success. Persistent losses increase the time and capital required before the pipeline can become self-sustaining.

Ongoing Cash Burn And Funding Dependence

Continued operating cash outflows mean the company cannot currently fund development from internal operations. It must rely on equity, debt, partnerships, or other external capital, creating recurring financing exposure as clinical programs become more expensive.

Constrained Financing Flexibility

Lender-protective financing terms restrict how new capital can be deployed and reduce management’s flexibility during a capital-intensive development period. This can limit resources available for operations or trials and increase dependence on additional financing.

PDS Biotechnology News

PDSB FAQ

What was PDS Biotechnology’s price range in the past 12 months?
PDS Biotechnology lowest stock price was $0.20 and its highest was $1.79 in the past 12 months.
What is PDS Biotechnology’s market cap?
PDS Biotechnology’s market cap is $82.33M.
When is PDS Biotechnology’s upcoming earnings report date?
PDS Biotechnology’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 132 days.
How were PDS Biotechnology’s earnings last quarter?
PDS Biotechnology released its earnings results on Nov 13, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.02.
Is PDS Biotechnology overvalued?
According to Wall Street analysts PDS Biotechnology’s price is currently Undervalued.
Does PDS Biotechnology pay dividends?
PDS Biotechnology does not currently pay dividends.
What is PDS Biotechnology’s EPS estimate?
PDS Biotechnology’s EPS estimate is -0.06.
How many shares outstanding does PDS Biotechnology have?
PDS Biotechnology has 105,005,430 shares outstanding.
What happened to PDS Biotechnology’s price movement after its last earnings report?
PDS Biotechnology reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -11.02%.
Which hedge fund is a major shareholder of PDS Biotechnology?
Hedge funds hold PDS Biotechnology shares: the largest hedge-fund position in PDS Biotechnology is 72,328,303 shares, and hedge funds decreased their holdings by 8.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology